Diakonos Oncology to Present Groundbreaking Data on DOC1021 in Cancer Treatment at 2026 Conferences Diakonos Oncology Corp. will unveil clinical trial results for DOC1021, an innovative immunotherapy for pancreatic cancer and glioblastoma, at AACR and AAN 2026.

Diakonos Oncology to Present Groundbreaking Data on DOC1021 in Cancer Treatment at 2026 Conferences #United_States #Houston #Cancer_Treatment #Diakonos_Oncology #DOC1021

Diakonos Oncology to Showcase Innovations at the 2026 Biotech Showcase in San Francisco Diakonos Oncology will present groundbreaking advancements in immunotherapy at the 2026 Biotech Showcase, highlighting their innovative therapy DOC1021 for aggressive cancers.

Diakonos Oncology to Showcase Innovations at the 2026 Biotech Showcase in San Francisco #United_States #San_Francisco #Biotech_Showcase #Diakonos_Oncology #DOC1021

Diakonos Oncology Secures Significant Funding to Investigate DOC1021 for Refractory Melanoma Diakonos Oncology has been awarded a $7 million grant to advance research on DOC1021 in refractory melanoma, showing promise in cancer treatment.

Diakonos Oncology Secures Significant Funding to Investigate DOC1021 for Refractory Melanoma #USA #Houston #Diakonos_Oncology #DOC1021 #Refractory_Melanoma

Exciting Phase 1 Data on DOC1021 Immunotherapy for Pancreatic Cancer Unveiled Diakonos Oncology reveals promising Phase 1 data for DOC1021 therapy in pancreatic cancer, showcasing a boost in patient survival rates.

Exciting Phase 1 Data on DOC1021 Immunotherapy for Pancreatic Cancer Unveiled #United_States #Houston #pancreatic_cancer #Diakonos_Oncology #DOC1021

Diakonos Oncology to Showcase Pancreatic Cancer Trial Data at SITC Annual Meeting Diakonos Oncology is set to present promising data from clinical trials on their innovative DOC1021 immunotherapy targeting pancreatic cancer at SITC 40th Annual Meeting.

Diakonos Oncology to Showcase Pancreatic Cancer Trial Data at SITC Annual Meeting #USA #pancreatic_cancer #Diakonos_Oncology #DOC1021 #National_Harbor,_MD

Diakonos Oncology Begins Phase 2 Trial of DOC1021 for Aggressive Glioblastoma Treatment Diakonos Oncology has announced the first patient has been dosed in a Phase 2 clinical trial evaluating DOC1021 for glioblastoma, a challenging and aggressive brain cancer.

Diakonos Oncology Begins Phase 2 Trial of DOC1021 for Aggressive Glioblastoma Treatment #USA #Los_Angeles #Glioblastoma #Diakonos_Oncology #DOC1021

Diakonos Oncology to Unveil Phase I Results of Novel Glioblastoma Therapy at ASCO 2025 Annual Meeting Diakonos Oncology Corp. announces its presentation of promising Phase I results for DOC1021, a groundbreaking therapy for glioblastoma, at ASCO 2025.

Diakonos Oncology to Unveil Phase I Results of Novel Glioblastoma Therapy at ASCO 2025 Annual Meeting #United_States #Glioblastoma #Chicago,_Illinois #Diakonos_Oncology #DOC1021

Promising Results for Diakonos Oncology's DOC1021 Presented at the 2025 AAN Annual Meeting Diakonos Oncology showcases highly encouraging Phase I trial results for DOC1021, a promising new treatment for glioblastoma, at the 2025 AAN Annual Meeting.

Promising Results for Diakonos Oncology's DOC1021 Presented at the 2025 AAN Annual Meeting #USA #San_Diego #Glioblastoma #Diakonos_Oncology #DOC1021

Diakonos Oncology Set to Showcase Innovative Cancer Treatments at Biotech Showcase 2025 Diakonos Oncology will present its groundbreaking cancer immunotherapy developments at Biotech Showcase 2025, highlighting its novel DOC1021 vaccine.

Diakonos Oncology Set to Showcase Innovative Cancer Treatments at Biotech Showcase 2025 #United_States #San_Francisco,_CA #Biotech_Showcase #Diakonos_Oncology #DOC1021